Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Revenue of Petros Pharmaceuticals, Inc. (PTPI)
Revenue in 2023 (TTM): $5.82 M
According to Petros Pharmaceuticals, Inc.'s latest financial reports the company's current revenue (TTM) is $5.82 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Petros Pharmaceuticals, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.82 M | $908.2 K | $-7,347,180 | $-8,163,188 | $-8,163,188 |
| 2022 | $5.99 M | $3.7 M | $-6,842,671 | $-20,037,573 | $-27,037,573 |
| 2021 | $7.81 M | $6.21 M | $-11,170,026 | $-8,986,676 | $-9,355,336 |
| 2020 | $9.56 M | $5.51 M | $-10,621,601 | $-22,012,918 | $-20,585,925 |
| 2019 | $15.58 M | $8.15 M | $-11,577,168 | $-33,157,166 | $-32,511,300 |
| 2018 | $14.05 M | $3.57 M | $414.72 K | $-32,486,072 | $-32,472,707 |